Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Dec 11;23(1):1386.
doi: 10.1186/s12913-023-10350-9.

Implementation strategies for hospital-based probiotic administration in a stepped-wedge cluster randomized trial design for preventing hospital-acquired Clostridioides difficile infection

Affiliations
Randomized Controlled Trial

Implementation strategies for hospital-based probiotic administration in a stepped-wedge cluster randomized trial design for preventing hospital-acquired Clostridioides difficile infection

Lauren C Bresee et al. BMC Health Serv Res. .

Abstract

Background: Clostridioides difficile infection (CDI) is associated with considerable morbidity and mortality in hospitalized patients, especially among older adults. Probiotics have been evaluated to prevent hospital-acquired (HA) CDI in patients who are receiving systemic antibiotics, but the implementation of timely probiotic administration remains a challenge. We evaluated methods for effective probiotic implementation across a large health region as part of a study to assess the real-world effectiveness of a probiotic to prevent HA-CDI (Prevent CDI-55 +).

Methods: We used a stepped-wedge cluster-randomized controlled trial across four acute-care adult hospitals (n = 2,490 beds) to implement the use of the probiotic Bio-K + ® (Lactobacillus acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®; Laval, Quebec, Canada) in patients 55 years and older receiving systemic antimicrobials. The multifaceted probiotic implementation strategy included electronic clinical decision support, local site champions, and both health care provider and patient educational interventions. Focus groups were conducted during study implementation to identify ongoing barriers and facilitators to probiotic implementation, guiding needed adaptations of the implementation strategy. Focus groups were thematically analyzed using the Theoretical Domains Framework and the Consolidated Framework of Implementation Research.

Results: A total of 340 education sessions with over 1,800 key partners and participants occurred before and during implementation in each of the four hospitals. Site champions were identified for each included hospital, and both electronic clinical decision support and printed educational resources were available to health care providers and patients. A total of 15 individuals participated in 2 focus group and 7 interviews. Key barriers identified from the focus groups resulted in adaptation of the electronic clinical decision support and the addition of nursing education related to probiotic administration. As a result of modifying implementation strategies for identified behaviour change barriers, probiotic adherence rates were from 66.7 to 75.8% at 72 h of starting antibiotic therapy across the four participating acute care hospitals.

Conclusions: Use of a barrier-targeted multifaceted approach, including electronic clinical decision support, education, focus groups to guide the adaptation of the implementation plan, and local site champions, resulted in a high probiotic adherence rate in the Prevent CDI-55 + study.

Keywords: Focus group; Hospital-acquired Clostridioides difficile Infection; Order entry; Probiotics; Protocol implementation.

PubMed Disclaimer

Conflict of interest statement

TL and OEL receive industry research funding from Finch Therapeutics, Rebiotix Inc, Crestone Inc, Artugen Therapeutics, Seres Therapeutics, ImmuniMed Inc, MGB Biopharma, Summit Therapeutics and Vedanta Biosciences for clinical trials of C. difficile therapeutics. All other authors had no competing interests to declare.

Figures

Fig. 1
Fig. 1
Prevent CDI-55 + study Basic Design. The clusters (C1, C2, C3, or C4) represent one hospital randomized to the four sequences where C = South Health Campus; C2 = Rockyview General Hospital; C3 = Peter Lougheed Centre; and C4 = Foothills Medical Centre. Each cluster included one or more 6-month control period(s) and an intervention minimum of one year. There was no transition time between periods

References

    1. Marra AR, Perencevich EN, Nelson RE, Samore M, Khader K, Chiang HY, et al. Incidence and outcomes associated with Clostridium difficile Infections: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(1):e1917597. doi: 10.1001/jamanetworkopen.2019.17597. - DOI - PMC - PubMed
    1. Leal JR, Conly J, Weaver R, Wick J, Henderson EA, Manns B, et al. Attributable costs and length of stay of hospital-acquired Clostridioides difficile: a population-based matched cohort study in Alberta, Canada. Infect Control Hosp Epidemiol. 2019;40(10):1135–1143. doi: 10.1017/ice.2019.178. - DOI - PubMed
    1. Mitchell BG, Gardner A. Mortality and Clostridium difficile Infection: a review. Antimicrob Resist Infect Control. 2012;1(1):20. doi: 10.1186/2047-2994-1-20. - DOI - PMC - PubMed
    1. Louh IK, Greendyke WG, Hermann EA, Davidson KW, Falzon L, Vawdrey DK, et al. Clostridium Difficile Infection in acute care hospitals: systematic review and best practices for prevention. Infect Control Hosp Epidemiol. 2017;38(4):476–482. doi: 10.1017/ice.2016.324. - DOI - PMC - PubMed
    1. Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile Infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016;48(1):1–10. doi: 10.1016/j.ijantimicag.2016.03.008. - DOI - PubMed

Publication types

Substances